a public good project by the
Synthesis
Company
of California

© 2026

Heidi A. Lane | doi.page

0 works0 citations0 h-index

Heidi A. Lane

Basilea Pharmaceutica (Switzerland)(CH)

Publications by Year

Research Areas

Microtubule and mitosis dynamics, PI3K/AKT/mTOR signaling in cancer, Cancer Treatment and Pharmacology, Glioma Diagnosis and Treatment, Estrogen and related hormone effects

Most-Cited Works

→ ERBB receptors and cancer: the complexity of targeted inhibitors(2005)3,292 cited
→ mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt(2006)2,544 cited
→ Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo(1995)962 cited
→ mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways(2004)956 cited
→ Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.(1996)689 cited
→ Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer(2009)658 cited

→ Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors(2008)

528 cited

→ Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function(2008)501 cited

→ The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation(2005)490 cited

→ Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors(2008)476 cited